Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium.
暂无分享，去创建一个
M. de Boer | V. Tjan-Heijnen | N. Peters | M. Joore | B. Ramaekers | T. Smilde | J. V. van Riel | F. van den Berkmortel | M. Dercksen | A. J. van de Wouw | F. Peters | R. V. van Kampen | D. Lobbezoo